Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash & Equivalents: 2018-2020

Historic Cash & Equivalents for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2020 value amounting to $34.6 million.

  • Black Diamond Therapeutics' Cash & Equivalents fell 17.07% to $46.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $46.6 million, marking a year-over-year decrease of 17.07%. This contributed to the annual value of $34.6 million for FY2020, which is 77.63% down from last year.
  • Per Black Diamond Therapeutics' latest filing, its Cash & Equivalents stood at $34.6 million for FY2020, which was down 77.63% from $154.7 million recorded in FY2019.
  • Over the past 5 years, Black Diamond Therapeutics' Cash & Equivalents peaked at $154.7 million during FY2019, and registered a low of $34.6 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $51.7 million (2018), whereas its average is $80.3 million.
  • As far as peak fluctuations go, Black Diamond Therapeutics' Cash & Equivalents soared by 199.39% in 2019, and later crashed by 77.63% in 2020.
  • Over the past 3 years, Black Diamond Therapeutics' Cash & Equivalents (Yearly) stood at $51.7 million in 2018, then skyrocketed by 199.39% to $154.7 million in 2019, then crashed by 77.63% to $34.6 million in 2020.